| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
BChE-IN-41 (compound (R)-(−)-3) (5 μM, 48 h) exhibited neuroprotective activity by reducing Aβ1−42-induced SH-SY5Y cell death [1].
|
|---|---|
| ln Vivo |
BChE-IN-41 (compound (R)-(−)-3) (10-100 mg/kg, gavage, single dose) is highly effective, has high brain penetration and low toxicity in wild-type Balb/c mice, and no histopathological changes were observed in the mice [1]. BChE-IN-41 (1-10 mg/kg, intraperitoneal injection, single dose) can improve scopolamine-induced episodic and cognitive memory deficits in adult male CD-1 mice [1]. BChE-IN-41 (10 mg/kg, intraperitoneal injection, continuous administration for 14 days) can improve the learning ability and cognitive function of Aβ1-42 oligomer-induced ICR male mice [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: HepG2 cells, SH-SY5Y cells Tested Concentrations: 1 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM Incubation Duration: 48 hours Experimental Results: Both HepG2 cells and SH-SY5Y cells showed similar cytotoxic characteristics. Cytotoxicity assay [1] Cell Types: SH-SY5Y cells Tested Concentrations: 2.5 μM, 5 μM Incubation Duration: 48 hours Experimental Results: The toxicity of Aβ was reversed and cell death was reduced at 5 μM; its effect was not significant at 2.5 μM. |
| Animal Protocol |
Animal/Disease Models:Female and male wild-type Balb/c mice (3 months old) [1]
Doses: 10 mg/kg, 100 mg/kg Route of Administration: Gavage (ig), single dose Experimental Results: High brain tissue penetration, brain-to-plasma ratio was 9.0. No mice died or suffered tissue damage, and no abnormalities were found in histological examination. Mice gained weight steadily, and no acute toxic reactions were observed. Animal/Disease Models:Scopolamine (1 mg/kg, subcutaneous injection) induced an AD model in adult male CD-1 mice (18–22 g) [1] Doses: 1 mg/kg, 10 mg/kg Route of Administration: Intraperitoneal injection (ip), single dose Experimental Results: Prolonged the latency to enter the dark room and improved episodic memory deficits. Compared with mice treated with scopolamine alone, the latency to cross the dark room was prolonged. Enhanced preference for novel objects, improved discrimination index (DI), and reversed recognition memory deficits. Animal/Disease Models:Aβ1-42 oligomers (10 µg per mouse, intraventricular injection) induced a cognitive impairment model similar to Alzheimer's disease (AD) in male ICR mice (8-10 weeks old, 18-20 g) [1]. Doses: 10 mg/kg. Route of Administration: Intraperitoneal injection (ip) for 14 consecutive days at the same dose as described above. Experimental Results: No motor dysfunction was observed in the rotarod test (6/18/24 rpm). It shortened escape latency and distance to the target area, and improved Aβ1-42-induced cognitive impairment. |
| References |
| Molecular Formula |
C23H26N2O2S
|
|---|---|
| Molecular Weight |
394.53
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CN(S(=O)(C1=CC=C(C=CC=C2)C2=C1)=O)C[C@@H](C3)CCN3CC4=CC=CC=C4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5347 mL | 12.6733 mL | 25.3466 mL | |
| 5 mM | 0.5069 mL | 2.5347 mL | 5.0693 mL | |
| 10 mM | 0.2535 mL | 1.2673 mL | 2.5347 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
